.Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04C_DrugsUsedInBenignProstaticHypertrophy.G04CA55_DoxazosinAndFinasteride.DoxazosinAndFinasteride .Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04C_DrugsUsedInBenignProstaticHypertrophy.G04CA55_DoxazosinAndFinasteride.DoxazosinAndFinasteride| name: | DoxazosinAndFinasteride | |
| ATC code: | G04CA55 | route: | oral |
| compartments: | 1 | |
| dosage: | 5 | mg |
| volume of distribution: | 40 | L |
| clearance: | 1.5 | L/h |
| other parameters in model implementation | ||
Doxazosin and finasteride is a combination drug used primarily in the treatment of benign prostatic hyperplasia (BPH) in men. Doxazosin is an alpha-1 adrenergic blocker that relaxes smooth muscle in the prostate and bladder neck, while finasteride is a 5-alpha-reductase inhibitor that lowers levels of dihydrotestosterone, resulting in shrinkage of the enlarged prostate. The fixed-dose combination is marketed in some regions but may not be universally approved or widely used.
No published population pharmacokinetic models for the fixed-dose combination of doxazosin and finasteride were identified. The following are estimates based on known pharmacokinetics of individual drugs in healthy adult males, assuming standard oral administration.